Harrow (NASDAQ:HROW) Stock Jumps 5% – Still a Buy?

Shares of Harrow, Inc. (NASDAQ:HROW) were up 5% during trading on Friday. The company traded as high as $29.14 and last traded at $29.7020. Approximately 27,980 shares were traded during mid-day trading, a decline of 96% from the average session volume of 695,777 shares. The stock had previously closed at $28.30.

More Harrow News

These are some of the HROW news items that stood out recently:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $0.40 from a loss of $0.57, and its Q2 2027 estimate to a loss of $0.10 from a loss of $0.12. The changes suggest some improvement in those periods. Harrow analyst estimate updates
• Neutral Sentiment: Harrow plans to participate in two investor conferences on November 17 and 18, including a presentation at the Jefferies Global Healthcare Conference. The events may give management a chance to discuss the business, but no new financial information was announced. Harrow investor conference announcement
• Negative Sentiment: HC Wainwright cut its FY2027 EPS estimate to $0.50 from $0.88, and its Q4 2027 forecast to $0.92 from $1.07. It also lowered its Q3 2027 estimate to $0.32 from $0.40. These reductions indicate a less optimistic earnings outlook, despite the increases to some other estimates. Harrow analyst estimate updates

Analyst Ratings Changes

Several analysts have weighed in on the stock. Leerink Partners started coverage on shares of Harrow in a research report on Wednesday, September 9th. They set an “outperform” rating and a $45.00 target price on the stock. BTIG Research reaffirmed a “buy” rating and issued a $63.00 price target on shares of Harrow in a report on Wednesday. Zacks Research downgraded shares of Harrow from a “hold” rating to a “strong sell” rating in a research note on Tuesday, November 3rd. Wall Street Zen raised shares of Harrow from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Harrow in a report on Friday, October 16th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $66.20.

Harrow Stock Performance

The stock has a market capitalization of $1.13 billion, a PE ratio of -38.61 and a beta of 0.18. The company has a quick ratio of 2.08, a current ratio of 2.29 and a debt-to-equity ratio of 10.15. The firm has a 50 day moving average price of $30.77 and a 200-day moving average price of $37.52.

Harrow (NASDAQ:HROW) last released its earnings results on Monday, November 9th. The company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.06. Harrow had a negative return on equity of 69.81% and a negative net margin of 9.39%. The firm had revenue of $99.30 million during the quarter, compared to the consensus estimate of $98.59 million. Research analysts expect that Harrow, Inc. will post -0.28 EPS for the current fiscal year.

Institutional Trading of Harrow

Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in Harrow during the 2nd quarter worth about $116,373,000. Bamco Inc. NY purchased a new position in shares of Harrow during the 2nd quarter valued at about $34,373,000. Jupiter Topco LLC purchased a new position in shares of Harrow during the 2nd quarter valued at about $24,596,000. Rice Hall James & Associates LLC acquired a new position in shares of Harrow in the 2nd quarter valued at about $16,459,000. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Harrow by 56.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 579,520 shares of the company’s stock valued at $20,428,000 after buying an additional 208,972 shares during the period. 72.76% of the stock is currently owned by institutional investors and hedge funds.

About Harrow

Harrow is a pharmaceutical company focused on developing, acquiring and commercializing treatments for eye conditions. Its portfolio includes prescription ophthalmic medicines used in areas such as dry eye disease, eye inflammation and pain management, as well as products used in eye surgery and clinical settings. The company markets branded products including VEVYE, a treatment for dry eye disease, and IHEEZO, an ophthalmic anesthetic gel. Through its ImprimisRx subsidiary, Harrow also provides compounded medications and related services for ophthalmology practices and patients.